Fig. 3From: Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectivesHighlights in the development of panobinostat which was firstly approved by the FDA to treat RRMM. Figure created with BioRender.comBack to article page